Date: 2016-06-21
Type of information: Opening of new premises
Compound: biosimilar laboratory
Company: Xbrane Biopharma (Sweden)
Therapeutic area:
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On June 21, 2016, Xbrane has completed the construction of a state of the art laboratory that allows significantly increased capacity and efficiency in the biosimilar development. The laboratory is located in Xbranes new facilities in Hagalunds industrial park in Solna outside Stockholm. The new equipment in combination with several key recruitments of specialists to the team allows Xbrane to accelerate the development of its biosimilars. The company has three biosimilars under development. Xlucane is a ranibizumab biosimilar for treatment of age related macula degeneration. Xcimzane is a biosimilar on the originator drug Cimzia® used in treatment of rheumatoid arthritis and Xoncane is a biosimilar on Oncaspar® used in treatment of acute lymphoblastic leukaemia.
Financial terms:
Latest news:
